Mark Boguniewicz
Concepts (517)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dermatitis, Atopic | 151 | 2024 | 310 | 22.530 |
Why?
| Eczema | 14 | 2023 | 82 | 3.150 |
Why?
| Antibodies, Monoclonal, Humanized | 17 | 2023 | 665 | 2.420 |
Why?
| Skin | 32 | 2024 | 659 | 2.010 |
Why?
| Severity of Illness Index | 43 | 2023 | 2551 | 1.900 |
Why?
| Tacrolimus | 20 | 2023 | 135 | 1.850 |
Why?
| Pruritus | 15 | 2023 | 60 | 1.520 |
Why?
| Dermatologic Agents | 13 | 2023 | 57 | 1.500 |
Why?
| Antibodies, Monoclonal | 7 | 2023 | 1268 | 1.460 |
Why?
| Quality of Life | 27 | 2023 | 2359 | 1.360 |
Why?
| Immunosuppressive Agents | 14 | 2023 | 651 | 1.240 |
Why?
| Staphylococcus aureus | 11 | 2023 | 385 | 1.160 |
Why?
| Staphylococcal Skin Infections | 6 | 2018 | 29 | 1.160 |
Why?
| Receptors, Aryl Hydrocarbon | 2 | 2024 | 39 | 1.120 |
Why?
| Keratinocytes | 11 | 2024 | 216 | 1.110 |
Why?
| Biological Products | 2 | 2020 | 171 | 1.110 |
Why?
| Asthma | 15 | 2023 | 2051 | 1.040 |
Why?
| Calcineurin Inhibitors | 14 | 2010 | 58 | 0.980 |
Why?
| Kaposi Varicelliform Eruption | 12 | 2013 | 24 | 0.950 |
Why?
| Humans | 170 | 2024 | 115049 | 0.870 |
Why?
| Practice Guidelines as Topic | 9 | 2018 | 1398 | 0.860 |
Why?
| Boron Compounds | 3 | 2018 | 17 | 0.770 |
Why?
| Immunoglobulin E | 18 | 2023 | 323 | 0.760 |
Why?
| Emollients | 4 | 2018 | 11 | 0.740 |
Why?
| Urticaria | 3 | 2008 | 50 | 0.740 |
Why?
| Double-Blind Method | 23 | 2023 | 1665 | 0.730 |
Why?
| Interleukin-4 Receptor alpha Subunit | 1 | 2020 | 7 | 0.730 |
Why?
| Hypersensitivity | 3 | 2023 | 256 | 0.720 |
Why?
| Intermediate Filament Proteins | 7 | 2018 | 65 | 0.700 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2018 | 172 | 0.690 |
Why?
| Adrenal Cortex Hormones | 10 | 2023 | 499 | 0.670 |
Why?
| Dermatology | 3 | 2017 | 86 | 0.670 |
Why?
| Bandages | 3 | 2016 | 31 | 0.660 |
Why?
| Administration, Topical | 15 | 2020 | 138 | 0.650 |
Why?
| Cytokines | 16 | 2023 | 1843 | 0.650 |
Why?
| Anti-Infective Agents | 5 | 2022 | 225 | 0.650 |
Why?
| Allergy and Immunology | 2 | 2017 | 53 | 0.640 |
Why?
| Expert Testimony | 1 | 2019 | 36 | 0.640 |
Why?
| Anti-Inflammatory Agents | 11 | 2020 | 451 | 0.630 |
Why?
| Skin Care | 4 | 2008 | 18 | 0.620 |
Why?
| Interferon-gamma | 11 | 2013 | 723 | 0.610 |
Why?
| Adult | 71 | 2023 | 30658 | 0.600 |
Why?
| Treatment Outcome | 29 | 2023 | 9123 | 0.600 |
Why?
| Biological Therapy | 1 | 2017 | 26 | 0.580 |
Why?
| Interleukin-13 | 10 | 2023 | 123 | 0.570 |
Why?
| Occlusive Dressings | 1 | 2016 | 5 | 0.560 |
Why?
| Antimicrobial Cationic Peptides | 5 | 2010 | 75 | 0.550 |
Why?
| Interleukin-4 | 9 | 2023 | 209 | 0.520 |
Why?
| Herpes Simplex | 3 | 2013 | 87 | 0.520 |
Why?
| Advisory Committees | 1 | 2017 | 208 | 0.510 |
Why?
| Psoriasis | 10 | 2023 | 74 | 0.510 |
Why?
| Anti-Asthmatic Agents | 1 | 2019 | 350 | 0.490 |
Why?
| Cost of Illness | 9 | 2018 | 254 | 0.490 |
Why?
| Education, Medical, Continuing | 1 | 2016 | 119 | 0.480 |
Why?
| Epidermis | 3 | 2017 | 149 | 0.470 |
Why?
| Conjunctivitis | 3 | 2023 | 17 | 0.450 |
Why?
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 3 | 2018 | 6 | 0.450 |
Why?
| Simplexvirus | 3 | 2011 | 80 | 0.450 |
Why?
| Autoimmune Diseases | 4 | 2018 | 394 | 0.450 |
Why?
| Glycyrrhetinic Acid | 3 | 2008 | 7 | 0.450 |
Why?
| Th2 Cells | 6 | 2017 | 155 | 0.440 |
Why?
| Molecular Targeted Therapy | 2 | 2020 | 347 | 0.440 |
Why?
| Anti-Allergic Agents | 3 | 2014 | 41 | 0.430 |
Why?
| Child | 40 | 2023 | 18407 | 0.420 |
Why?
| Hypersensitivity, Immediate | 3 | 2019 | 46 | 0.420 |
Why?
| Calcineurin | 5 | 2006 | 89 | 0.410 |
Why?
| Desensitization, Immunologic | 4 | 2022 | 117 | 0.410 |
Why?
| beta-Defensins | 7 | 2010 | 18 | 0.410 |
Why?
| Child, Preschool | 30 | 2018 | 9093 | 0.400 |
Why?
| Immunity, Innate | 6 | 2011 | 723 | 0.390 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 299 | 0.380 |
Why?
| Allergens | 7 | 2023 | 417 | 0.360 |
Why?
| Adolescent | 33 | 2023 | 17864 | 0.350 |
Why?
| Drug Approval | 3 | 2020 | 78 | 0.350 |
Why?
| Ointments | 10 | 2016 | 23 | 0.350 |
Why?
| Clinical Trials as Topic | 4 | 2020 | 937 | 0.350 |
Why?
| Food Hypersensitivity | 5 | 2018 | 254 | 0.350 |
Why?
| Adaptive Immunity | 1 | 2011 | 156 | 0.350 |
Why?
| Plant Extracts | 3 | 2008 | 154 | 0.350 |
Why?
| Disease Progression | 6 | 2019 | 2389 | 0.340 |
Why?
| Complementary Therapies | 1 | 2010 | 72 | 0.340 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 191 | 0.340 |
Why?
| Staphylococcal Infections | 4 | 2023 | 336 | 0.330 |
Why?
| Dietary Fats | 2 | 2008 | 290 | 0.330 |
Why?
| Drug Hypersensitivity | 3 | 1995 | 85 | 0.320 |
Why?
| Off-Label Use | 2 | 2020 | 52 | 0.320 |
Why?
| Prevalence | 12 | 2019 | 2255 | 0.320 |
Why?
| Inflammation | 4 | 2018 | 2485 | 0.310 |
Why?
| Receptors, IgE | 1 | 2008 | 40 | 0.310 |
Why?
| Administration, Cutaneous | 8 | 2016 | 117 | 0.310 |
Why?
| Population Groups | 2 | 2018 | 57 | 0.310 |
Why?
| Male | 51 | 2023 | 55735 | 0.300 |
Why?
| Chronic Disease | 12 | 2019 | 1591 | 0.300 |
Why?
| Self Report | 7 | 2019 | 698 | 0.300 |
Why?
| Disease Management | 5 | 2020 | 563 | 0.290 |
Why?
| United States | 19 | 2023 | 12227 | 0.290 |
Why?
| Cross-Sectional Studies | 14 | 2021 | 4411 | 0.270 |
Why?
| Anti-Bacterial Agents | 6 | 2023 | 1477 | 0.270 |
Why?
| Female | 49 | 2023 | 59617 | 0.260 |
Why?
| Dermatitis, Allergic Contact | 2 | 2016 | 63 | 0.250 |
Why?
| Vaccinia virus | 4 | 2011 | 28 | 0.250 |
Why?
| Patch Tests | 3 | 2016 | 52 | 0.250 |
Why?
| Phototherapy | 3 | 2018 | 24 | 0.250 |
Why?
| Infant | 22 | 2022 | 7946 | 0.240 |
Why?
| Omalizumab | 2 | 2020 | 46 | 0.240 |
Why?
| Steroids | 3 | 2017 | 147 | 0.240 |
Why?
| Exanthema | 1 | 2005 | 76 | 0.230 |
Why?
| Diagnosis, Differential | 7 | 2008 | 1355 | 0.230 |
Why?
| Anxiety | 3 | 2019 | 845 | 0.230 |
Why?
| Janus Kinase Inhibitors | 1 | 2023 | 10 | 0.230 |
Why?
| Middle Aged | 34 | 2019 | 26830 | 0.220 |
Why?
| Janus Kinases | 1 | 2023 | 12 | 0.220 |
Why?
| Ectropion | 1 | 2023 | 2 | 0.220 |
Why?
| Blepharitis | 1 | 2023 | 3 | 0.220 |
Why?
| Down-Regulation | 7 | 2017 | 599 | 0.220 |
Why?
| Pain | 2 | 2019 | 709 | 0.220 |
Why?
| Sublingual Immunotherapy | 1 | 2022 | 7 | 0.210 |
Why?
| Receptors, Interleukin | 3 | 2020 | 39 | 0.210 |
Why?
| Depression | 3 | 2019 | 1136 | 0.200 |
Why?
| Tight Junctions | 3 | 2011 | 68 | 0.200 |
Why?
| Sickness Impact Profile | 2 | 2019 | 50 | 0.200 |
Why?
| Recurrence | 4 | 2019 | 941 | 0.200 |
Why?
| Drug Industry | 2 | 2018 | 104 | 0.190 |
Why?
| STAT6 Transcription Factor | 3 | 2011 | 22 | 0.190 |
Why?
| Membrane Proteins | 4 | 2011 | 1019 | 0.190 |
Why?
| Patient Education as Topic | 5 | 2015 | 682 | 0.180 |
Why?
| Autoantibodies | 1 | 2008 | 1354 | 0.180 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 117 | 0.180 |
Why?
| Consensus | 3 | 2017 | 534 | 0.180 |
Why?
| Bacterial Toxins | 3 | 2012 | 103 | 0.180 |
Why?
| Biomarkers | 6 | 2023 | 3419 | 0.180 |
Why?
| Animals | 16 | 2023 | 31868 | 0.170 |
Why?
| Injections, Subcutaneous | 4 | 2023 | 133 | 0.170 |
Why?
| Pyrimidines | 1 | 2022 | 376 | 0.170 |
Why?
| Skin Diseases, Infectious | 3 | 2008 | 15 | 0.160 |
Why?
| Patient Health Questionnaire | 1 | 2018 | 20 | 0.160 |
Why?
| Sulfonamides | 1 | 2022 | 446 | 0.160 |
Why?
| Surveys and Questionnaires | 5 | 2019 | 4631 | 0.160 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2018 | 82 | 0.160 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2023 | 1215 | 0.150 |
Why?
| Injections | 1 | 2019 | 159 | 0.150 |
Why?
| Patient Reported Outcome Measures | 4 | 2022 | 250 | 0.150 |
Why?
| Genetic Predisposition to Disease | 6 | 2011 | 2108 | 0.150 |
Why?
| T-Lymphocytes | 6 | 2006 | 1747 | 0.150 |
Why?
| Sleep Wake Disorders | 1 | 2021 | 232 | 0.150 |
Why?
| Immunologic Factors | 2 | 2005 | 221 | 0.150 |
Why?
| Guidelines as Topic | 2 | 2018 | 245 | 0.150 |
Why?
| Gene Expression Regulation | 6 | 2011 | 2329 | 0.140 |
Why?
| Skin Diseases | 1 | 2019 | 122 | 0.140 |
Why?
| Practice Patterns, Physicians' | 2 | 2017 | 1178 | 0.140 |
Why?
| Skin Diseases, Viral | 2 | 2018 | 4 | 0.140 |
Why?
| Personal Satisfaction | 1 | 2018 | 182 | 0.140 |
Why?
| Evidence-Based Medicine | 2 | 2018 | 676 | 0.130 |
Why?
| Gloves, Surgical | 1 | 1996 | 3 | 0.130 |
Why?
| Gloves, Protective | 1 | 1996 | 2 | 0.130 |
Why?
| Latex | 1 | 1996 | 9 | 0.130 |
Why?
| Rubber | 1 | 1996 | 8 | 0.130 |
Why?
| Patient Acceptance of Health Care | 2 | 2019 | 679 | 0.130 |
Why?
| Cells, Cultured | 13 | 2011 | 3896 | 0.130 |
Why?
| Bronchial Hyperreactivity | 1 | 1996 | 95 | 0.130 |
Why?
| Dermatitis, Occupational | 1 | 1996 | 13 | 0.130 |
Why?
| Histamine H1 Antagonists | 2 | 2006 | 33 | 0.130 |
Why?
| Chemokines, CC | 3 | 2006 | 28 | 0.130 |
Why?
| Primary Health Care | 2 | 2016 | 1512 | 0.130 |
Why?
| Receptors, Cytokine | 2 | 2010 | 33 | 0.130 |
Why?
| Clinical Decision-Making | 1 | 2018 | 267 | 0.120 |
Why?
| Milk Proteins | 1 | 2015 | 36 | 0.120 |
Why?
| Ambulatory Care | 1 | 2019 | 478 | 0.120 |
Why?
| T-Lymphocyte Subsets | 2 | 2011 | 383 | 0.120 |
Why?
| Milk Hypersensitivity | 1 | 2015 | 22 | 0.120 |
Why?
| Gene Expression Profiling | 4 | 2011 | 1523 | 0.120 |
Why?
| Hydrotherapy | 1 | 2014 | 8 | 0.120 |
Why?
| Patient Care Planning | 1 | 2015 | 139 | 0.120 |
Why?
| Patient-Centered Care | 2 | 2018 | 474 | 0.120 |
Why?
| Infant Formula | 1 | 2015 | 74 | 0.120 |
Why?
| Risk Factors | 8 | 2015 | 8642 | 0.120 |
Why?
| Algorithms | 3 | 2018 | 1489 | 0.120 |
Why?
| Skin Tests | 3 | 2012 | 123 | 0.120 |
Why?
| Comorbidity | 5 | 2018 | 1457 | 0.110 |
Why?
| Aged | 13 | 2019 | 19122 | 0.110 |
Why?
| HLA-B7 Antigen | 1 | 2013 | 7 | 0.110 |
Why?
| Recombinant Proteins | 6 | 2006 | 1237 | 0.110 |
Why?
| Network Meta-Analysis | 2 | 2023 | 15 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 5 | 2020 | 1857 | 0.110 |
Why?
| Lipids | 1 | 2017 | 586 | 0.110 |
Why?
| Young Adult | 10 | 2019 | 10498 | 0.110 |
Why?
| Health Status | 1 | 2018 | 722 | 0.110 |
Why?
| Logistic Models | 4 | 2019 | 1839 | 0.110 |
Why?
| Cholecalciferol | 1 | 2013 | 47 | 0.110 |
Why?
| Drug Administration Schedule | 4 | 2020 | 719 | 0.100 |
Why?
| RNA, Messenger | 9 | 2007 | 2563 | 0.100 |
Why?
| Interferon Regulatory Factor-2 | 1 | 2011 | 4 | 0.100 |
Why?
| Research Design | 1 | 2018 | 930 | 0.100 |
Why?
| Vitamins | 1 | 2013 | 151 | 0.100 |
Why?
| Immunity, Cellular | 1 | 2013 | 249 | 0.100 |
Why?
| Vitamin D | 2 | 2013 | 340 | 0.100 |
Why?
| Physical Therapy Modalities | 1 | 2014 | 265 | 0.100 |
Why?
| Mice, Transgenic | 3 | 2011 | 1955 | 0.100 |
Why?
| Signal Transduction | 2 | 2023 | 4525 | 0.100 |
Why?
| Polymorphism, Single Nucleotide | 7 | 2011 | 1901 | 0.100 |
Why?
| CD4-Positive T-Lymphocytes | 3 | 2010 | 965 | 0.090 |
Why?
| Guideline Adherence | 1 | 2015 | 492 | 0.090 |
Why?
| Pharmaceutical Vehicles | 2 | 2008 | 11 | 0.090 |
Why?
| Glucocorticoids | 2 | 2013 | 535 | 0.090 |
Why?
| Th1-Th2 Balance | 1 | 2010 | 10 | 0.090 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2011 | 144 | 0.090 |
Why?
| Histamine Antagonists | 1 | 2010 | 20 | 0.090 |
Why?
| Receptors, Chemokine | 1 | 2010 | 43 | 0.090 |
Why?
| Chickenpox Vaccine | 1 | 2010 | 69 | 0.090 |
Why?
| Therapies, Investigational | 1 | 2010 | 14 | 0.090 |
Why?
| Receptors, Interleukin-7 | 1 | 2010 | 25 | 0.090 |
Why?
| Hypertension | 1 | 2018 | 1058 | 0.090 |
Why?
| Cardiovascular Diseases | 2 | 2018 | 1729 | 0.090 |
Why?
| Mice | 9 | 2012 | 14928 | 0.090 |
Why?
| Genetic Variation | 2 | 2011 | 876 | 0.080 |
Why?
| Age Factors | 4 | 2019 | 2894 | 0.080 |
Why?
| Dietary Supplements | 1 | 2013 | 458 | 0.080 |
Why?
| Herpesviridae Infections | 1 | 2010 | 138 | 0.080 |
Why?
| Disease Outbreaks | 1 | 2012 | 309 | 0.080 |
Why?
| Pediatrics | 2 | 2015 | 981 | 0.080 |
Why?
| Adjuvants, Immunologic | 3 | 2004 | 206 | 0.080 |
Why?
| Aged, 80 and over | 6 | 2019 | 6357 | 0.080 |
Why?
| Drug Therapy, Combination | 3 | 2015 | 955 | 0.080 |
Why?
| Coal Tar | 1 | 2008 | 2 | 0.080 |
Why?
| Keratolytic Agents | 1 | 2008 | 5 | 0.080 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 744 | 0.080 |
Why?
| Cell Degranulation | 1 | 2008 | 39 | 0.080 |
Why?
| Environmental Exposure | 1 | 2012 | 377 | 0.080 |
Why?
| Pyroglyphidae | 2 | 2022 | 17 | 0.080 |
Why?
| Phenotype | 4 | 2023 | 2815 | 0.080 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2013 | 691 | 0.080 |
Why?
| Irritants | 1 | 2008 | 41 | 0.080 |
Why?
| Basophils | 1 | 2008 | 64 | 0.080 |
Why?
| Quality Improvement | 1 | 2016 | 953 | 0.080 |
Why?
| Dosage Forms | 1 | 2008 | 10 | 0.080 |
Why?
| United Kingdom | 2 | 2019 | 227 | 0.080 |
Why?
| Emergency Service, Hospital | 1 | 2019 | 1812 | 0.080 |
Why?
| Polymorphism, Genetic | 1 | 2011 | 617 | 0.080 |
Why?
| S100 Proteins | 1 | 2008 | 38 | 0.080 |
Why?
| Mast Cells | 1 | 2008 | 117 | 0.070 |
Why?
| Combined Modality Therapy | 3 | 2014 | 1127 | 0.070 |
Why?
| Reference Values | 2 | 2019 | 748 | 0.070 |
Why?
| Cathelicidins | 4 | 2010 | 38 | 0.070 |
Why?
| Clinical Protocols | 1 | 2008 | 234 | 0.070 |
Why?
| Protein Precursors | 1 | 2007 | 119 | 0.070 |
Why?
| Drug Combinations | 3 | 2020 | 287 | 0.070 |
Why?
| Macrophage Inflammatory Proteins | 1 | 2006 | 12 | 0.070 |
Why?
| Herpesvirus 3, Human | 1 | 2010 | 380 | 0.070 |
Why?
| Immunohistochemistry | 6 | 2010 | 1634 | 0.070 |
Why?
| Virus Replication | 2 | 2006 | 393 | 0.070 |
Why?
| Patient Dropouts | 1 | 2007 | 66 | 0.070 |
Why?
| Cost-Benefit Analysis | 3 | 2018 | 544 | 0.070 |
Why?
| Disease Susceptibility | 2 | 2020 | 316 | 0.070 |
Why?
| Lymphocyte Activation | 3 | 2010 | 1042 | 0.070 |
Why?
| Nonprescription Drugs | 1 | 2007 | 68 | 0.070 |
Why?
| Receptors, Lymphocyte Homing | 1 | 2006 | 15 | 0.070 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2006 | 54 | 0.070 |
Why?
| Proteins | 2 | 2010 | 915 | 0.070 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2011 | 1138 | 0.060 |
Why?
| Immunoglobulins | 2 | 2005 | 143 | 0.060 |
Why?
| Gene Frequency | 3 | 2013 | 483 | 0.060 |
Why?
| Thiazoles | 1 | 2006 | 110 | 0.060 |
Why?
| Thyroid Diseases | 1 | 2005 | 30 | 0.060 |
Why?
| Models, Immunological | 1 | 2005 | 92 | 0.060 |
Why?
| Immunoglobulin G | 2 | 2023 | 776 | 0.060 |
Why?
| Academies and Institutes | 1 | 2004 | 44 | 0.060 |
Why?
| Hyaluronic Acid | 1 | 2006 | 189 | 0.060 |
Why?
| Resorcinols | 1 | 2023 | 4 | 0.060 |
Why?
| Interleukins | 1 | 2006 | 236 | 0.060 |
Why?
| Patient Care Team | 1 | 2008 | 515 | 0.060 |
Why?
| Stilbenes | 1 | 2023 | 36 | 0.060 |
Why?
| Lactams | 2 | 1995 | 18 | 0.060 |
Why?
| Statistics, Nonparametric | 2 | 2019 | 387 | 0.060 |
Why?
| Acute Disease | 6 | 2008 | 915 | 0.060 |
Why?
| Membrane Glycoproteins | 1 | 2006 | 429 | 0.060 |
Why?
| Janus Kinase 1 | 1 | 2023 | 23 | 0.060 |
Why?
| Interleukin-10 | 1 | 2005 | 297 | 0.060 |
Why?
| Leukocyte Count | 2 | 1995 | 292 | 0.060 |
Why?
| STAT Transcription Factors | 1 | 2023 | 13 | 0.060 |
Why?
| Interleukin-11 | 1 | 2003 | 9 | 0.050 |
Why?
| Prednisone | 2 | 1994 | 231 | 0.050 |
Why?
| Risk | 2 | 2018 | 815 | 0.050 |
Why?
| Patient Compliance | 1 | 2007 | 524 | 0.050 |
Why?
| Caregivers | 2 | 2023 | 712 | 0.050 |
Why?
| Prognosis | 3 | 2018 | 3335 | 0.050 |
Why?
| Dermatophagoides pteronyssinus | 1 | 2022 | 3 | 0.050 |
Why?
| Prospective Studies | 2 | 2020 | 6232 | 0.050 |
Why?
| Conflict of Interest | 1 | 2004 | 119 | 0.050 |
Why?
| Fibronectins | 1 | 2023 | 108 | 0.050 |
Why?
| Interleukin-17 | 1 | 2003 | 104 | 0.050 |
Why?
| Respiratory Sounds | 1 | 2023 | 111 | 0.050 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2022 | 59 | 0.050 |
Why?
| Lymphoma | 2 | 2018 | 178 | 0.050 |
Why?
| Granuloma, Respiratory Tract | 1 | 2002 | 12 | 0.050 |
Why?
| Leukocytes, Mononuclear | 3 | 2013 | 496 | 0.050 |
Why?
| Immunotherapy | 1 | 2006 | 474 | 0.050 |
Why?
| Insurance, Physician Services | 1 | 2002 | 3 | 0.050 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2022 | 82 | 0.050 |
Why?
| Baths | 1 | 2022 | 17 | 0.050 |
Why?
| Langerhans Cells | 1 | 2001 | 11 | 0.050 |
Why?
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2001 | 12 | 0.050 |
Why?
| Eosinophils | 2 | 1995 | 281 | 0.050 |
Why?
| Disease Models, Animal | 1 | 2011 | 3545 | 0.050 |
Why?
| North America | 1 | 2022 | 259 | 0.050 |
Why?
| Ceramides | 1 | 2022 | 94 | 0.050 |
Why?
| Time Factors | 2 | 2007 | 6141 | 0.050 |
Why?
| Interleukin-15 | 1 | 2002 | 75 | 0.050 |
Why?
| Longitudinal Studies | 2 | 2019 | 2389 | 0.050 |
Why?
| Diet | 2 | 2022 | 1076 | 0.050 |
Why?
| Claudin-1 | 2 | 2011 | 21 | 0.050 |
Why?
| Gene Expression | 3 | 2007 | 1423 | 0.050 |
Why?
| Beryllium | 1 | 2002 | 146 | 0.050 |
Why?
| Bayes Theorem | 1 | 2022 | 331 | 0.050 |
Why?
| Placebos | 1 | 2021 | 198 | 0.050 |
Why?
| Monocyte Chemoattractant Proteins | 1 | 2000 | 8 | 0.040 |
Why?
| Health Expenditures | 1 | 2002 | 171 | 0.040 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 797 | 0.040 |
Why?
| Injection Site Reaction | 1 | 2020 | 3 | 0.040 |
Why?
| Markov Chains | 2 | 2015 | 114 | 0.040 |
Why?
| Risk Assessment | 2 | 2019 | 2976 | 0.040 |
Why?
| Chemokines, CXC | 2 | 2003 | 58 | 0.040 |
Why?
| Fatty Acids | 1 | 2022 | 385 | 0.040 |
Why?
| Leg Dermatoses | 1 | 2019 | 1 | 0.040 |
Why?
| Scalp Dermatoses | 1 | 2019 | 2 | 0.040 |
Why?
| Bronchoalveolar Lavage Fluid | 3 | 2002 | 590 | 0.040 |
Why?
| Foot Dermatoses | 1 | 2019 | 4 | 0.040 |
Why?
| Buttocks | 1 | 2019 | 10 | 0.040 |
Why?
| Facial Dermatoses | 1 | 2019 | 14 | 0.040 |
Why?
| Hand Dermatoses | 1 | 2019 | 7 | 0.040 |
Why?
| Genitalia | 1 | 2019 | 28 | 0.040 |
Why?
| Biopsy | 4 | 2007 | 1046 | 0.040 |
Why?
| Smallpox Vaccine | 2 | 2011 | 22 | 0.040 |
Why?
| Infection Control | 1 | 2020 | 135 | 0.040 |
Why?
| Genetic Association Studies | 2 | 2011 | 344 | 0.040 |
Why?
| Haplotypes | 2 | 2011 | 455 | 0.040 |
Why?
| Torso | 1 | 2019 | 30 | 0.040 |
Why?
| Interleukin-16 | 1 | 1998 | 6 | 0.040 |
Why?
| Autoantigens | 1 | 2001 | 397 | 0.040 |
Why?
| Dysbiosis | 1 | 2020 | 146 | 0.040 |
Why?
| Acetamides | 1 | 2018 | 25 | 0.040 |
Why?
| Canada | 1 | 2020 | 322 | 0.040 |
Why?
| Association | 1 | 2018 | 11 | 0.040 |
Why?
| Thalidomide | 1 | 2018 | 28 | 0.040 |
Why?
| Skin Diseases, Bacterial | 1 | 2018 | 22 | 0.040 |
Why?
| Phthalic Acids | 1 | 2018 | 28 | 0.040 |
Why?
| Arm | 1 | 2019 | 104 | 0.040 |
Why?
| Rhinitis, Allergic, Seasonal | 1 | 2018 | 32 | 0.040 |
Why?
| Colony Count, Microbial | 1 | 2018 | 111 | 0.040 |
Why?
| Pilot Projects | 2 | 1995 | 1375 | 0.040 |
Why?
| Medicaid | 1 | 2002 | 409 | 0.040 |
Why?
| Age Distribution | 1 | 2018 | 340 | 0.040 |
Why?
| Herpesvirus 2, Human | 2 | 2009 | 27 | 0.040 |
Why?
| Sex Distribution | 1 | 2018 | 335 | 0.040 |
Why?
| Fundoplication | 1 | 1997 | 51 | 0.040 |
Why?
| Immune System | 1 | 2018 | 172 | 0.040 |
Why?
| United States Food and Drug Administration | 1 | 2018 | 172 | 0.040 |
Why?
| Proteomics | 1 | 2023 | 844 | 0.040 |
Why?
| Quinazolines | 1 | 2018 | 240 | 0.040 |
Why?
| Peak Expiratory Flow Rate | 2 | 1993 | 33 | 0.040 |
Why?
| Psychiatric Status Rating Scales | 1 | 2019 | 484 | 0.030 |
Why?
| Monocytes | 2 | 2002 | 503 | 0.030 |
Why?
| Educational Status | 1 | 2019 | 412 | 0.030 |
Why?
| Texas | 2 | 2008 | 187 | 0.030 |
Why?
| Forced Expiratory Volume | 2 | 1997 | 476 | 0.030 |
Why?
| Psychometrics | 1 | 2019 | 608 | 0.030 |
Why?
| Health Occupations | 1 | 1996 | 28 | 0.030 |
Why?
| Rhinitis, Allergic | 1 | 2016 | 35 | 0.030 |
Why?
| Interleukin-12 | 1 | 1996 | 110 | 0.030 |
Why?
| Feasibility Studies | 1 | 2018 | 746 | 0.030 |
Why?
| Sleep | 1 | 2021 | 631 | 0.030 |
Why?
| Penicillins | 1 | 1995 | 52 | 0.030 |
Why?
| Genetic Linkage | 1 | 1996 | 297 | 0.030 |
Why?
| Whey Proteins | 1 | 2015 | 5 | 0.030 |
Why?
| Pyridines | 1 | 2018 | 426 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 928 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2019 | 1435 | 0.030 |
Why?
| Gastroesophageal Reflux | 1 | 1997 | 233 | 0.030 |
Why?
| Intraoperative Complications | 1 | 1996 | 124 | 0.030 |
Why?
| Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 364 | 0.030 |
Why?
| Cohort Studies | 2 | 2015 | 4904 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2019 | 1081 | 0.030 |
Why?
| Legionellosis | 1 | 1994 | 2 | 0.030 |
Why?
| Legionnaires' Disease | 1 | 1994 | 4 | 0.030 |
Why?
| Polymerase Chain Reaction | 2 | 2010 | 999 | 0.030 |
Why?
| Dermatitis, Irritant | 2 | 2004 | 11 | 0.030 |
Why?
| Long-Term Care | 1 | 2015 | 76 | 0.030 |
Why?
| Pneumonia, Pneumocystis | 1 | 1994 | 26 | 0.030 |
Why?
| Nebulizers and Vaporizers | 1 | 1995 | 78 | 0.030 |
Why?
| Milk | 1 | 2015 | 124 | 0.030 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 140 | 0.030 |
Why?
| Antigens | 1 | 1996 | 318 | 0.030 |
Why?
| ROC Curve | 1 | 2015 | 447 | 0.030 |
Why?
| Methylprednisolone | 1 | 1994 | 82 | 0.030 |
Why?
| Case-Control Studies | 2 | 2013 | 3015 | 0.030 |
Why?
| Respiratory Physiological Phenomena | 1 | 1993 | 29 | 0.030 |
Why?
| Immunologic Memory | 1 | 1996 | 313 | 0.030 |
Why?
| Sex Factors | 1 | 2019 | 1721 | 0.030 |
Why?
| Laparoscopy | 1 | 1997 | 387 | 0.030 |
Why?
| Chemokine CXCL10 | 2 | 2009 | 34 | 0.030 |
Why?
| Anaphylaxis | 1 | 1996 | 148 | 0.030 |
Why?
| Healthcare Disparities | 1 | 2019 | 480 | 0.030 |
Why?
| Mice, Inbred BALB C | 2 | 2006 | 1153 | 0.030 |
Why?
| Interdisciplinary Communication | 1 | 2014 | 185 | 0.030 |
Why?
| Genotype | 1 | 2018 | 1780 | 0.030 |
Why?
| Respiratory System | 1 | 1993 | 138 | 0.030 |
Why?
| Mice, Knockout | 2 | 2011 | 2585 | 0.030 |
Why?
| Chemokines | 2 | 2006 | 213 | 0.030 |
Why?
| Cockroaches | 1 | 2012 | 21 | 0.030 |
Why?
| Treatment Failure | 1 | 1993 | 332 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2019 | 2799 | 0.030 |
Why?
| Haptens | 1 | 1992 | 21 | 0.030 |
Why?
| Patient Care | 1 | 2013 | 103 | 0.030 |
Why?
| Cats | 1 | 2012 | 205 | 0.020 |
Why?
| Vaccinia | 1 | 2011 | 18 | 0.020 |
Why?
| Microbiota | 1 | 2019 | 648 | 0.020 |
Why?
| Family | 1 | 2015 | 591 | 0.020 |
Why?
| Models, Theoretical | 1 | 2015 | 517 | 0.020 |
Why?
| Enterocolitis, Pseudomembranous | 1 | 1991 | 25 | 0.020 |
Why?
| Dogs | 1 | 2012 | 340 | 0.020 |
Why?
| Lung Diseases | 1 | 1997 | 703 | 0.020 |
Why?
| Receptors, Interferon | 1 | 2011 | 47 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2015 | 1812 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2011 | 396 | 0.020 |
Why?
| Hospitalization | 1 | 2019 | 1755 | 0.020 |
Why?
| Antigens, Viral | 1 | 2010 | 176 | 0.020 |
Why?
| Mutation | 2 | 2011 | 3350 | 0.020 |
Why?
| Incidence | 1 | 1996 | 2318 | 0.020 |
Why?
| Chemokine CCL27 | 1 | 2009 | 1 | 0.020 |
Why?
| Chemokine CCL17 | 1 | 2009 | 4 | 0.020 |
Why?
| Health Care Costs | 2 | 2003 | 381 | 0.020 |
Why?
| Lung | 1 | 2002 | 3595 | 0.020 |
Why?
| Age of Onset | 1 | 2010 | 449 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2010 | 372 | 0.020 |
Why?
| Interferon-beta | 1 | 2009 | 79 | 0.020 |
Why?
| Skin Physiological Phenomena | 1 | 2008 | 26 | 0.020 |
Why?
| Herpesvirus 1, Human | 1 | 2009 | 77 | 0.020 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 107 | 0.020 |
Why?
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 14 | 0.020 |
Why?
| Health Personnel | 1 | 2013 | 574 | 0.020 |
Why?
| Fluticasone | 1 | 2007 | 87 | 0.020 |
Why?
| Chemokine CCL20 | 1 | 2006 | 4 | 0.020 |
Why?
| In Situ Hybridization | 2 | 1998 | 292 | 0.020 |
Why?
| Androstadienes | 1 | 2007 | 97 | 0.020 |
Why?
| Thiazolidines | 1 | 2006 | 7 | 0.020 |
Why?
| Obesity | 1 | 2018 | 2524 | 0.020 |
Why?
| Toll-Like Receptor 3 | 1 | 2006 | 26 | 0.020 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 84 | 0.020 |
Why?
| Vitis | 1 | 2006 | 38 | 0.020 |
Why?
| Antibodies, Viral | 1 | 2009 | 522 | 0.020 |
Why?
| Apoptosis | 1 | 1995 | 2366 | 0.020 |
Why?
| Europe | 1 | 2006 | 336 | 0.020 |
Why?
| Genomics | 1 | 2010 | 641 | 0.020 |
Why?
| Analysis of Variance | 1 | 2008 | 1229 | 0.020 |
Why?
| Product Surveillance, Postmarketing | 1 | 2005 | 63 | 0.020 |
Why?
| Erythema | 1 | 2004 | 25 | 0.020 |
Why?
| Infant, Newborn | 1 | 2015 | 5040 | 0.010 |
Why?
| Neoplasms, Experimental | 1 | 2005 | 151 | 0.010 |
Why?
| Antigens, Neoplasm | 1 | 2006 | 222 | 0.010 |
Why?
| Case Management | 1 | 2004 | 62 | 0.010 |
Why?
| Rats | 1 | 2012 | 4973 | 0.010 |
Why?
| DNA, Viral | 1 | 2006 | 349 | 0.010 |
Why?
| Inflammation Mediators | 1 | 2006 | 476 | 0.010 |
Why?
| Collagen Type III | 1 | 2003 | 18 | 0.010 |
Why?
| Retreatment | 1 | 2003 | 67 | 0.010 |
Why?
| Dendritic Cells | 1 | 2006 | 436 | 0.010 |
Why?
| Societies, Medical | 1 | 2006 | 678 | 0.010 |
Why?
| Collagen Type I | 1 | 2003 | 108 | 0.010 |
Why?
| Cell Line | 1 | 2008 | 2645 | 0.010 |
Why?
| Genes, T-Cell Receptor beta | 1 | 2002 | 18 | 0.010 |
Why?
| Calcium | 1 | 2008 | 1104 | 0.010 |
Why?
| Administration, Oral | 1 | 2004 | 730 | 0.010 |
Why?
| Immunophenotyping | 1 | 2003 | 276 | 0.010 |
Why?
| Transforming Growth Factor beta1 | 1 | 2003 | 154 | 0.010 |
Why?
| Insurance, Health, Reimbursement | 1 | 2003 | 88 | 0.010 |
Why?
| Base Sequence | 1 | 2006 | 2119 | 0.010 |
Why?
| Cooperative Behavior | 1 | 2004 | 383 | 0.010 |
Why?
| Health Services | 1 | 2003 | 103 | 0.010 |
Why?
| Biopsy, Needle | 1 | 2002 | 183 | 0.010 |
Why?
| Cell Differentiation | 1 | 2008 | 1700 | 0.010 |
Why?
| Patient Satisfaction | 1 | 2004 | 580 | 0.010 |
Why?
| Chemotactic Factors, Eosinophil | 1 | 2000 | 6 | 0.010 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 309 | 0.010 |
Why?
| Chemokine CCL11 | 1 | 2000 | 22 | 0.010 |
Why?
| Up-Regulation | 1 | 2003 | 812 | 0.010 |
Why?
| Transforming Growth Factor beta | 1 | 2003 | 448 | 0.010 |
Why?
| Odds Ratio | 1 | 2003 | 957 | 0.010 |
Why?
| Drug Prescriptions | 1 | 2002 | 239 | 0.010 |
Why?
| Receptors, Interleukin-5 | 1 | 1998 | 5 | 0.010 |
Why?
| Receptors, Interleukin-12 | 1 | 1998 | 6 | 0.010 |
Why?
| Receptors, Interleukin-4 | 1 | 1998 | 15 | 0.010 |
Why?
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 12 | 0.010 |
Why?
| Flow Cytometry | 1 | 2002 | 1084 | 0.010 |
Why?
| Retrospective Studies | 2 | 2006 | 12548 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 2002 | 1990 | 0.010 |
Why?
| Cell Movement | 1 | 2002 | 866 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 2002 | 2796 | 0.010 |
Why?
| Models, Biological | 1 | 2004 | 1636 | 0.010 |
Why?
| Colorado | 1 | 2006 | 4089 | 0.010 |
Why?
| Respiratory Function Tests | 1 | 1997 | 523 | 0.010 |
Why?
| Immunocompetence | 1 | 1994 | 40 | 0.010 |
Why?
| Interleukin-5 | 1 | 1994 | 30 | 0.010 |
Why?
| Methacholine Chloride | 1 | 1993 | 47 | 0.010 |
Why?
| Bronchial Provocation Tests | 1 | 1993 | 53 | 0.010 |
Why?
| Fatal Outcome | 1 | 1994 | 285 | 0.010 |
Why?
| Aerosols | 1 | 1993 | 151 | 0.010 |
Why?
| Interleukin-8 | 1 | 1993 | 238 | 0.010 |
Why?
| Macrophage Activation | 1 | 1993 | 164 | 0.010 |
Why?
| Bronchi | 1 | 1993 | 243 | 0.010 |
Why?
| Administration, Inhalation | 1 | 1993 | 641 | 0.010 |
Why?
| Neoplasms | 1 | 2005 | 2106 | 0.010 |
Why?
| Cell Survival | 1 | 1995 | 1022 | 0.010 |
Why?
| Enterotoxins | 1 | 1991 | 88 | 0.010 |
Why?
| Macrophages, Alveolar | 1 | 1993 | 351 | 0.010 |
Why?
| Antibodies, Bacterial | 1 | 1991 | 119 | 0.010 |
Why?
| Immunoglobulins, Intravenous | 1 | 1991 | 121 | 0.010 |
Why?
| Interleukin-1 | 1 | 1993 | 970 | 0.010 |
Why?
| Transcription, Genetic | 1 | 1993 | 1317 | 0.000 |
Why?
|
|
Boguniewicz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|